Daprodustat

Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor — BLOOD AND BLOOD FORMING ORGANS

Key facts

Daprodustat is an ofm drug in the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor class catalogued in DrugCentral. It was first approved by the PMDA in 2020. Its mechanism of action is classified as Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors. DrugCentral lists 6 molecular targets, including EGLN1, EGLN3 and EGLN2. Recorded indications include Anemia in chronic kidney disease and Anemia of renal disease.

• Approval status: ofm (first approved 2020 by the PMDA).
• Drug class: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor.
• Mechanism of action: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors.
• Molecular targets: EGLN1, EGLN3, EGLN2 and ASPH (6 listed in DrugCentral).
• Indications: Anemia in chronic kidney disease and Anemia of renal disease.
• ATC code: B03XA07 (Other antianemic preparations).
• Molecular formula: C19H27N3O6; molecular weight 393.44 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Anemia in chronic kidney disease
• Anemia of renal disease

Contraindications (2)

• Concomitant administration of strong CYP2C8 inhibitors
• Uncontrolled hypertension

Mechanism & targets

• Mechanism of action (MoA): Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
• Established pharmacologic class: Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor

Molecular targets (6)

Target	Gene	Action	Activity
Egl nine homolog 1	EGLN1	inhibitor	IC50 8.46
Egl nine homolog 3	EGLN3	inhibitor	IC50 8.26
Egl nine homolog 2	EGLN2	inhibitor	IC50 8.14
Aspartyl/asparaginyl beta-hydroxylase	ASPH	unknown	IC50 4.96
Gamma-butyrobetaine dioxygenase	BBOX1	unknown	IC50 4.89
Hypoxia-inducible factor 1-alpha inhibitor	HIF1AN	unknown	IC50 4.68

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2023-02-01	FDA	—	GLAXOSMITHKLINE
2020-06-29	PMDA	—	GlaxoSmithKline

ATC classification

ATC code	Therapeutic hierarchy
B03XA07	BLOOD AND BLOOD FORMING ORGANS › ANTIANEMIC PREPARATIONS › OTHER ANTIANEMIC PREPARATIONS › Other antianemic preparations

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hospitalisation	745.8
Marasmus	341.1
Haemoglobin increased	306.1
Product use issue	209.2
Cerebral infarction	152.4
Renal impairment	151.8
Cardiac failure	142.1
Haemoglobin decreased	137.0
Dysphagia	116.5
Fracture	91.8
Dialysis	83.2
Death	70.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Daprodustat is on its molecule page.

• Molecular formula: C₁₉H₂₇N₃O₆
• Molecular weight: 393.44 g/mol
• CAS number: —
• InChIKey: RUEYEZADQJCKGV-UHFFFAOYSA-N
• PubChem CID: 91617630

C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Daprodustat used for?

DrugCentral lists the following indications for Daprodustat: Anemia in chronic kidney disease and Anemia of renal disease.

How does Daprodustat work?

Daprodustat is classified as Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors; its molecular targets in DrugCentral include EGLN1 (inhibitor), EGLN3 (inhibitor), EGLN2 (inhibitor) and ASPH.

When was Daprodustat first approved?

Daprodustat was first approved by the PMDA in 2020.

What drug class does Daprodustat belong to?

Daprodustat is in the Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor class.

What is the chemical formula of Daprodustat?

Daprodustat has the molecular formula C19H27N3O6 and a molecular weight of 393.44 g/mol.

Sources

• DrugCentral drug card 5421 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3544988 — compound record and bioactivity
• PubChem CID 91617630 — chemical identifiers
• DrugBank DB11682 — drug record
• FDA UNII JVR38ZM64B — substance identity
• DailyMed: FDA labels for Daprodustat — current prescribing information (label search)
• UniProt Q9GZT9 (EGLN1) — target protein
• UniProt Q9H6Z9 (EGLN3) — target protein
• UniProt Q96KS0 (EGLN2) — target protein
• UniProt Q12797 (ASPH) — target protein
• UniProt O75936 (BBOX1) — target protein
• UniProt Q9NWT6 (HIF1AN) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.